Schnitzler G, Queisser W, Heim M E, König H, Katz R, Fritze D, Herrmann R, Arnold H, Henss H, Trux F A
Cancer Treat Rep. 1986 Apr;70(4):477-9.
Seventy-seven patients with advanced gastric carcinoma were prospectively randomized to receive 5-FU and carmustine (FB) with or without doxorubicin (FAB). Thirty-five patients were evaluable for response. Neither the response rates (partial remission, 11% for FB and 24% for FAB) nor survival times (median, 4.0 months for FB and 5.5 months for FAB) were statistically different. The median survival of patients with partial remission (7.8 months) and those with no change (7.4 months) was significantly prolonged compared to patients with progressive disease (4.5 months). The side effects of both regimens after the first treatment cycle (except alopecia in FAB) were low. After the second cycle more pronounced myelosuppression in the FAB arm was observed.
77例晚期胃癌患者被前瞻性随机分为两组，一组接受5-氟尿嘧啶和卡莫司汀（FB）治疗，另一组在FB基础上加用阿霉素（FAB）治疗。35例患者可进行疗效评估。两组的缓解率（部分缓解，FB组为11%，FAB组为24%）和生存时间（中位数，FB组为4.0个月，FAB组为5.5个月）均无统计学差异。部分缓解患者（7.8个月）和病情无变化患者（7.4个月）的中位生存期显著长于疾病进展患者（4.5个月）。第一个治疗周期后，两种治疗方案的副作用（FAB组的脱发除外）均较低。第二个周期后，观察到FAB组有更明显的骨髓抑制。
